Rebiotix, a Ferring Company, Completes Enrollment for First-Ever, Pivotal Phase 3 Clinical Trial of Microbiota-based RBX2660 By webadmin|2020-02-05T18:08:42-05:00February 4th, 2020|Uncategorized|0 Comments Read More
Vedanta Biosciences Announces Initiation of First-in-Patient Study of Immuno-Oncology Candidate VE800 In Combination with Bristol-Myers Squibb’s Opdivo® (Nivolumab) By webadmin|2020-01-10T00:17:58-05:00December 5th, 2019|Uncategorized|0 Comments Read More
Interview with Jim Weston and Stephen Conafay of MTIG By webadmin|2019-10-01T14:34:05-04:00October 1st, 2019|Uncategorized|0 Comments Read More
Microbiome Therapeutics Innovation Group Highlights Member Company Activity at IDWeek 2019 By webadmin|2019-10-01T13:08:59-04:00October 1st, 2019|Uncategorized|0 Comments Read More
LUCA Biologics Launches to Develop Live Biotherapeutics for Women’s Health Starting with Urinary Tract Infection (UTI) By webadmin|2019-08-07T10:46:10-04:00August 7th, 2019|Uncategorized|0 Comments Read More
Seed Health Joins Microbiome Therapeutics Innovation Group By webadmin|2019-07-16T10:27:29-04:00July 16th, 2019|Uncategorized|0 Comments Read More
Rebiotix Leaders to Discuss Microbiome Product Development Challenges and Regulation at Microbiome Movement – Drug Development Summit 2019 By webadmin|2019-07-01T11:30:27-04:00July 1st, 2019|Uncategorized|0 Comments Read More
Microbiome Therapeutics Innovation Group Statement on FDA Safety Alert Regarding Use of Fecal Microbiota for Transplantation and Risk of Serious Adverse Reactions Due to Transmission of Multi-Drug Resistant Organisms By webadmin|2019-06-17T10:45:10-04:00June 17th, 2019|Uncategorized|0 Comments Read More
MTIG Position Statement for FMT By webadmin|2019-06-14T14:01:03-04:00March 14th, 2019|Uncategorized|0 Comments Read More
The Microbiome Therapeutics Innovation Group Announces Coalition Formation and Leadership Team By webadmin|2018-08-14T14:11:51-04:00August 14th, 2018|Uncategorized|0 Comments Read More
